Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model November 5, 2018

Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model

view full story

Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer November 5, 2018

Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer

view full story

Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center November 1, 2018

Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

view full story

Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress October 22, 2018

Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress

view full story

Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency October 17, 2018

Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency

view full story

Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma October 12, 2018

Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

view full story

Cavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study October 5, 2018

Cavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study

view full story

Nimbus Therapeutics Names Jeb Keiper as President and Chief Executive Officer October 4, 2018

Nimbus Therapeutics Names Jeb Keiper as President and Chief Executive Officer

view full story

Cavion to Announce Results of its Phase 2 Essential Tremor Clinical Trial October 4, 2018

Cavion to Announce Results of its Phase 2 Essential Tremor Clinical Trial

view full story

FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency October 1, 2018

FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency

view full story

Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300 September 27, 2018

Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300

view full story

Sutro Biopharma Announces $85.0 Million Initial Public Offering September 26, 2018

Sutro Biopharma Announces $85.0 Million Initial Public Offering

view full story

Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer September 20, 2018

Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer

view full story

Cavion Appoints Julia P. Gregory Executive Chair September 11, 2018

Cavion Appoints Julia P. Gregory Executive Chair

view full story

Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer September 6, 2018

Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer

view full story

Aeglea Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1-2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency September 4, 2018

Aeglea Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1-2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency

view full story

FDA Grants Orphan Drug Designation to Surface Oncology’s SRF231 for the Treatment of Multiple Myeloma July 30, 2018

FDA Grants Orphan Drug Designation to Surface Oncology’s SRF231 for the Treatment of Multiple Myeloma

view full story

Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders July 24, 2018

Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders

view full story

Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer July 19, 2018

Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer

view full story

Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors July 16, 2018

Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors

view full story

Nimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology July 9, 2018

Nimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology

view full story

Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting June 18, 2018

Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting

view full story

Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930 June 12, 2018

Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930

view full story

Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts June 5, 2018

Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts

view full story